Reference
Laskari K, et al. The interleukin-1 inhibitor canakinumab for familial mediterranean fever: Long-term beneficial effect in a cohort of 14 patients. Annals of the Rheumatic Diseases 75: 618-619 abstr. FRI0497, Jun 2016. Available from: URL: http://ard.bmj.com/content/75/Suppl_2/618.3.abstract?sid=5d849280-ee26-42a5-af4a-aabe0a2f07ad [abstract] - Greece
Rights and permissions
About this article
Cite this article
Canakinumab. Reactions Weekly 1626, 45 (2016). https://doi.org/10.1007/s40278-016-22626-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-016-22626-1